AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06115408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2 MG
Description: Clinical trial
Study NCT06115408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Clinical trial
Study NCT04864509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: Nightly dose
Study NCT04864509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nightly dose
Study NCT04823520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA
Description: All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
Study NCT05311098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: Treatment of atrial fibrillation with cryoablation catheters
Study NCT06065865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance document
Description: The main intervention of interest is the guidance document, which is explained under 'Arms'. Within the treatment trajectory, that is based on the guidance document, the participants can receive a combination of NIKA, and parent and child can both get EMDR-therapy. The therapies are combined in one treatment trajectory.~NIKA consists of 5 weekly sessions during which participants are videotaped by a trained therapist. The therapist will provide personalized feedback to the parent, which is focused on reducing disrupted parenting behavior and increasing sensitive parenting behavior. EMDR is a brief trauma therapy (in this trial a maximum of six 90-min sessions for the parent and a maximum of six 60-min sessions for the child) aimed at reducing the negative load of the memories of traumatic events. Both parent and child can receive this therapy. During the weekly sessions, the participant is asked to bring the traumatic event to mind while the therapist provides a distracting task.
Study NCT06312748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: 100 mg tablet
Study NCT06312748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for L-Citrulline
Description: L-Citrulline-matched Placebo tablet
Study NCT06312748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4
Description: 10mg/kg
Study NCT06312748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BH4
Description: BH4-matched Placebo
Study NCT06312748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg tablet
Study NCT06312748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin
Description: Atorvastatin-matched Placebo
Study NCT05074849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion
Description: A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
Study NCT05968287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Leukocyte ImmunoTest™ (LIT™)
Description: The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.
Study NCT05662410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three monthly injections of intravitreal aflibercept
Description: Three monthly intravitreal injection of aflibercept (2.0mg / 0.05ml) after diagnosis of pathychoroid neovasculopathy.
Study NCT04726462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional exercises
Description: The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
Study NCT04726462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture exercises
Description: The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
Study NCT06357351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibular incision sub periosteal tunnel access ( VISTA) technique.
Description: In comparison between the two groups, the first group uses collagen membrane and the other group uses advanced PRF using the same surgical technique (VISTA)
Study NCT06486311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: satellite implant
Description: Satellite implant is a additional holding component as a stabilizer to provide a polygonal support to distribute forces and moments on single-standing implants give the implant sufficient resistance to withstand masticatory forces or at least keep it in a stable position during an unloaded healing period to achieve stabilization and subsequent osseointegration of implants.
Study NCT06398860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIOHPS
Description: The intervention is comprised of several core components such as targeted education, daily team reflections and support for systematic management. First, a two hour education will be conducted for management, HCW involved in patient safety work, safety representatives and intervention facilitators. The second core component is a short daily team reflection conducted by HCW at the unit in connection to the end of work shifts. These are standardized to support identification of situations at work related to both Safety I and II perspective for both occupational health and patient safety as well as learning. The third component includes risk assessment, planning and implementation of appropriate measures, follow up and evaluation, based in information identified in the second component. The steps in this component targets the management and should be conducted in close collaboration with HCW involved in patient safety work and the safety representatives.
Study NCT06398860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wait-list
Description: No intervention
Study NCT05364372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom assessment only
Description: Dyads will receive 12 weekly phone calls to assess symptom management.
Study NCT05364372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom management and lifestyle intervention
Description: Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
Study NCT05147623 — intervention group
Intervention type: PROCEDURE
Intervention: Any surgery/procedure
Description: Any surgery/procedure in all adult patients that were performed in an operating room
Study NCT04718155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: will receive 40 mg atrorvastatin 2 days
Study NCT04718155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: will receive 40 mg placebo 2 days
Study NCT06515197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Music
Description: Participants in this group will listen to pre-selected motivational music tracks for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The aim is to assess the impact of motivational music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
Study NCT06515197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Selected Music
Description: Participants in this group will choose their own music to listen to for 30 minutes before each basketball training and performance test. This intervention will be conducted three times a week for 12 weeks. The goal is to determine the effect of self-selected music on mental energy, mental toughness, psychological skills, mindfulness, athletic identity, and sports performance.
Study NCT05718310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: 25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
Study NCT05718310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
Study NCT05087485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: digital education in skin cancer diagnostics
Study NCT05317754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful breathing
Description: * Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary.
Study NCT05317754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostrations, according to Tibetan Buddhist tradition
Description: * Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary.
Study NCT05317754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Koan Mu, according to Zen Buddhist tradition
Description: * Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary.
Study NCT05317754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The mirror exercise, according to Toltec tradition
Description: * Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary.
Study NCT04431817 — intervention group
Intervention type: DEVICE
Intervention: KinetiGait
Description: This device is an Intel RGB depth camera that relays video to gait analysis software. The images will be taken from amputees walking at a self-selected pace on a treadmill.
Study NCT05494060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
Study NCT05494060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab Injection
Description: Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
Study NCT05494060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Study NCT05494060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Study NCT04910646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orange peel fermentation
Description: To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.
Study NCT04910646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without orange peel fermentation
Study NCT04731766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Citrine 5 % sodium fluoride
Description: Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
Study NCT04731766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: concocted nano-silver fluoride
Description: Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
Study NCT06433804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HER2 IHC
Description: Immunohistochemistry for HER2
Study NCT06200298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block with naropeine [3,75 mg/mL]
Description: Erector spinae plane block Procedure:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~* Repetition of the gesture for the transverse controlateral process
Study NCT06200298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB with saline 0,9%
Description: Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process
Study NCT05822453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
Study NCT05822453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle
Study NCT05822453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
Study NCT06078280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System (CPM)
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study NCT05023395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEE-HU Medicus
Description: This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.
Study NCT05023395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04034550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and urine sampling and blood banking
Description: In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
Study NCT04740892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash IP
Description: Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
Study NCT04740892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream IP
Description: Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
Study NCT05309434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach
Description: The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
Study NCT04717284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (SCI)
Description: All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
Study NCT04717284 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control condition
Description: All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
Study NCT05411367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-614
Description: 1 drop in each eye
Study NCT05411367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye
Study NCT06050954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab (200mg)
Description: 200mg Pembrolizumab every six weeks via IV infusion.
Study NCT06050954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab (400mg)
Description: 400mg Pembrolizumab every six weeks via IV infusion.
Study NCT06050954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Monitoring
Description: active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
Study NCT05492188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant Conditioning of Cutaneous Reflexes
Description: This is a training intervention in which people with a spinal cord injury are trained to change (increase or decrease) the activity of a certain spinal reflex. By changing this reflex, it is hypothesized that individuals can reduce pain due to spinal cord injury.
Study NCT04758299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decision science-based design
Description: decision science-based design explaining actions to take for a negative or positive COVID-19 test